Marksans Pharma Limited
NSE: MARKSANSINE750C01026(was TASCPHARMA)·HealthcareMicrocap 250·www.marksanspharma.com ↗·Mcap ₹15,745 Cr·Listed 2002
₹336.95▼ ₹0.45  (−0.13%)
52W: ₹155 – ₹351 · Vol: 14.5L shares · Close 25 Sept
Set Alert

Quarterly results

consolidated · as filed with NSE · Q1 FY27 back to Q4 FY18
₹ croreQ1 FY27Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q3 FY25Q2 FY25Q1 FY25Q4 FY24Q3 FY24Q2 FY24Q1 FY24Q4 FY23Q3 FY23Q2 FY23Q1 FY23Q4 FY22Q3 FY22Q2 FY22Q1 FY22Q4 FY21Q3 FY21Q2 FY21Q1 FY21Q4 FY20Q3 FY20Q2 FY20Q1 FY20Q4 FY19Q3 FY19Q2 FY19Q1 FY19Q4 FY18
Revenue from operations84185675472062070.8682642591560586531500486480453434418363361349330358356331335288256245247248269235913
Other income25.435.220.121.65.61.727.811.114.916.54.81910.11117.714.216.515.312.18.65.96−3.23.70.2007.92.29.70.2−0.83.20.4
Total expenses66069162460954960.9566528486476478436413393418389374381314310280239278294270278249231220240219241208863
EBITDA21319516114410012.613913612811013311410211076.680.372.963.657.860.177.395.491.183.27069.247.333.632.415.636.237.135.586.5
EBITDA margin25.3%22.8%21.3%20.1%16.1%17.8%20.4%21.1%21.7%19.6%22.7%21.4%20.4%22.5%16.0%17.7%16.8%15.2%15.9%16.6%22.2%28.9%25.4%23.3%21.1%20.6%16.4%13.1%13.2%6.3%14.6%13.8%15.1%9.5%
Finance costs76.35.95.86.10.32.72.62.94.83.21.61.62.42.42.51.8511.512.81.71.91.621.62.82.32.41.83.12.410.2
Depreciation24.924.324.326.923.12.320.719.520.421.12217.613.713.912.714.111.121.48.67.47.51.38.6197.29.67.354.76.355.5626.8
Profit before tax20720015113376.611.614312512010011311496.810479.277.876.452.660.459.874.897.277.665.961.457.638.333.727.616.729.627.730.449.8
Tax47.25136.934.218.42.538.226.83122.629.729.926.421.516.917.716.322.912.113.512.217.718.715.21214.88.87.75.16.84.47.25.514
Net profit15914911499.158.29.110597.889.177.68383.970.482.762.360.160.229.748.346.362.679.558.950.749.442.729.62622.59.925.120.624.935.8
Net margin19.0%17.4%15.1%13.8%9.4%12.8%15.4%15.2%15.1%13.9%14.2%15.8%14.1%17.0%13.0%13.3%13.9%7.1%13.3%12.8%17.9%24.1%16.4%14.2%14.9%12.7%10.3%10.1%9.2%4.0%10.1%7.6%10.6%3.9%
EPS (₹)3.473.272.502.171.292.002.312.131.961.731.841.841.521.971.561.521.460.691.201.111.511.931.421.211.201.000.710.630.520.210.600.480.580.80
Net profit YoY+173.9%+1542.7%+8.2%+1.4%−34.7%−88.3%+26.6%+16.6%+26.4%−6.1%+33.2%+39.5%+17.0%+178.9%+29.1%+29.9%−3.9%−62.7%−18.1%−8.8%+26.8%+86.0%+99.4%+95.4%+119.6%+333.8%+17.6%+26.2%−9.6%−72.5%––––

Annual results

financial years ending March · from the fourth-quarter filings
₹ croreFY26FY25FY24FY23FY22FY21FY20FY19FY18
Revenue from operations2,9512622,1771,8521,4911,3761,1341,000767
Other income82.5750.459.341.96.70.34.67
Total expenses2,4732191,8041,5741,2851,081977900759
EBITDA60152.945933925934019213244.7
EBITDA margin20.4%20.2%21.1%18.3%17.4%24.7%17.0%13.2%5.8%
Finance costs24.11.211.29.18.488.79.76.8
Depreciation98.68.374.351.944.836.226.722.830.1
Profit before tax56150.442433824830215710414.9
Tax14012.110972.360.763.636.423.93.6
Net profit42038.331526518723912180.411.3
Net margin14.2%14.6%14.5%14.3%12.5%17.3%10.6%8.0%1.5%
EPS (₹)9.228.406.926.414.515.762.861.870.22
Net profit YoY+997.9%−87.8%+18.7%+42.0%−21.7%+97.5%+50.1%+609.6%–
EPS is as filed for each period and is not restated for later bonus issues or splits.

Cash flow

annual · ₹ crore
₹ croreFY26FY25FY24FY23FY22
Operating cash flow45820.723023799.3
Investing cash flow−248−4.9−141−259−41.7
Financing cash flow−70.9−6.5−68.719879.5
Capital expenditure13117.320953.646.3
Free cash flow (CFO − capex)3283.421.618452.9

Net profit trend

annual, ₹ crore
FY21
₹239
FY22
₹187−22%
FY23
₹265+42%
FY24
₹315+19%
FY25
₹38.3−88%
FY26
₹420+998%

Result filings

as filed with NSE · PDF and XBRL
PeriodBasisFiledDocuments
Q1 FY27Consolidated12 Aug 2026PDF on NSE XBRL
Q1 FY27Standalone12 Aug 2026PDF on NSE XBRL
Q4 FY26Consolidated · audited26 May 2026PDF on NSE XBRL
Q4 FY26Standalone · audited26 May 2026PDF on NSE XBRL
Q3 FY26Consolidated5 Feb 2026PDF on NSE XBRL
Q3 FY26Standalone5 Feb 2026PDF on NSE XBRL
Q2 FY26Consolidated13 Nov 2025PDF on NSE XBRL
Q2 FY26Standalone13 Nov 2025PDF on NSE XBRL
Q1 FY26Consolidated12 Aug 2025PDF on NSE XBRL
Q1 FY26Standalone12 Aug 2025PDF on NSE XBRL

Annual reports

NSE archive
Key ratios
P/E (TTM)5Y avg 78.6×29.3×
P/B5Y avg 7.68×5.05×
ROEFY26, on average equity25.7%
Net margin14.2%
Debt / equity0.01×
Revenue CAGR (3Y)16.8%
Profit CAGR (3Y)16.6%
EPS (TTM)₹11.50
Market cap₹15,269 Cr
Computed from the filings and the last close. Market cap uses the latest share count from the balance sheet.
P/B vs history
5.05×
vs 8-point avg 7.68× (−34%)
1.67× low7.68× avg40.87× high
History points are balance-sheet dates (2022 → 2026), priced at the adjusted close on each date.
Balance sheet 31 Mar 2026
Total assets₹3,861 Cr+1092%
Net worth₹3,023 Cr+1125%
Total borrowings₹30 Cr+1182%
Cash & bank balances₹634 Cr+1179%
Investments₹0 Cr−100%
Inventories₹972 Cr+1050%
Trade receivables₹645 Cr+1094%
Trade payables₹337 Cr+1002%
Change vs the same date a year earlier.
Shareholding 30 Jun 2026
%Jun 26Mar 26Dec 25Sept 25Jun 25Mar 25Dec 24Sept 24Jun 24Mar 24Dec 23Sept 23
Promoter43.8743.8743.8743.8743.8743.8743.8743.8743.8743.8543.8543.85
FII17.4716.7616.7416.9219.8822.2021.9621.3118.6015.5715.5615.07
DII6.196.575.915.285.504.564.304.103.755.174.764.02
of which MF4.364.664.413.923.55–––––––
Retail28.0528.3328.9829.5326.7425.7826.2426.7629.4730.9130.8032.12
Other public4.424.474.504.404.013.593.633.964.314.505.034.94
2,46,635 shareholders · NSE shareholding pattern filings.